Merrill keeps Acambis at neutral

Merrill Lynch analyst Erica Whittaker kept Acambis plc at a neutral rating after the company's second-quarter financial results missed the analyst's forecasts due to a £2 million revenue shortfall. Acambis secured revenues from the U.S. government for 10 million doses of ACAM2000 smallpox vaccine for $30 million, in line with Merrill's expectations of 10 million doses for $31 million. Shares of the Cambridge, England-based pharmaceutical company were up 8.00p, or 5.88%, at 144.00p. (London: ACM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.